Novo Nordisk Fair Value
NO
The fair market value of NOVC.DU stock is 91.48 EUR. Relative to the market price of 0 EUR Novo Nordisk A/S is overvalued by 22.6%
Eyestock's quantitative valuation approach is based on the method of estimating historical multipliers. To determine whether a stock is undervalued, we compare its current price to our estimated of fair value. The more undervalued a stock is, the more investment is profitable.
Fair Relative Value
Novo Nordisk Valuation
The fair value level of 91.48 EUR can be considered as an effective entry point for long-term investors to start investing in NOVC.DU stock. For a more in-depth assessment, we provide a minimum value that can be used to increase a stock position and a maximum one that can be used to reduce it.
Price chart is not available
Current market price
Market price:
NOVC.DU stock is greatly overvalued
It means the current price may concern as a High Risk Entry Point
Novo Nordisk A/S Stock Valuation Calculator
How do we value a stock?
As fair value, we use the product of the median Price-to-earnings ratios at the end of each reporting period for the last 5 years and earnings per share for the last 12 months. By analogy with the fair value, we calculate the maximum and minimum ones using the corresponding P/E extremums.
1
Maximum P/E over 5 years
30.19
2
Median P/E over 5 years
26.01
3
Minimum P/E over 5 years
18.42
4
Earning per share (last 12 months)
26.25 DKK
Maximum value
1
x
4
=
106.2 EUR
Fair value
2
x
4
=
91.48 EUR
Minimum value
3
x
4
=
64.79 EUR
Novo Nordisk A/S price metrics
40.7
Annual return (geometric mean)
27.9
Risk (standard deviation) of returns
β
1.4
Beta (volatility compared to market)